

研究分担者：武田伸一

1. Kobayashi M, Nakamura A, Hasegawa D, Fujita M, Orima H, ○Takeda S: Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging., *Muscle Nerve*, 40, 815-826, 2009
2. Nakamura A, ○Takeda S: Exon-skipping therapy for Duchenne muscular dystrophy., *Neuropathology*, 29, 494-501, 2009
3. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, ○Takeda S, Hoffman E: Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs., *Ann Neurol*, 65, 667-676, 2009
4. Miyazaki D, Yoshida K, Fukushima K, Nakamura A, Suzuki K, Sato T, ○Takeda S, Ikeda SI: Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene., *J Hum Genet*, 54,127-130, 2009
5. Miyagoe-Suzuki Y, Masubuchi N, Miyamoto K, Wada MR, Yuasa S, Saito F, Matsumura KI, Kanesaki H, Kudo A, Manya H, Endo T, ○Takeda S: Reduced proliferative activity of primary POMGnT1-null myoblasts in vitro., *Mech Dev.*, 126, 107-116, 2009
6. Yokota T, ○Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP: A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground., *Arch Neurol*, 66, 32-38, 2009
7. Ohshima S, Shin JH, Yuasa K, Nishiyama A, Kira J, Okada T, ○Takeda S: Transduction Efficiency and Immune Response Associated With the Administration of AAV8 Vector Into Dog Skeletal Muscle., *Mol Ther*, 17, 73-80, 2009
8. Sato K, Yokota T, Ichioka S, Shibata M, ○Takeda S: Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression., *Acta Myol*, 27,30-36, 2008
9. Yuasa K, Hagiwara Y, Ando M, Nakamura A, ○Takeda S, Hijikata T: MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy., *Cell Struct Funct*, 33, 163-169, 2008
10. Motohashi N, Uezumi A, Yada E, Fukada SI, Fukushima K, Imaizumi K, Miyagoe-Suzuki Y, ○Takeda S: Muscle CD31(-) CD45(-) Side Population Cells Promote Muscle Regeneration by Stimulating Proliferation and Migration of Myoblasts., *Am J Pathol*, 173, 781-791, 2008
11. Nishiyama A, Ampong BN, Ohshima S, Shin JH, Nakai H, Imamura M, Miyagoe-Suzuki Y, Okada T, ○Takeda S: Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice., *Hum Gene Ther* , 19, 719-730, 2008

12. Nakamura A, Yoshida K, Fukushima K, Ueda H, Urasawa N, Koyama J, Yazaki Y, Yazaki M, Sakai T, Haruta S, O Takeda S, Ikeda S: Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene., *J Clin Neurosci*, 15, 757-763, 2008
13. Urasawa N, Wada MR, Machida N, Yuasa K, Shimatsu Y, Wakao Y, Yuasa S, Sano T, Nonaka I, Nakamura A, O Takeda S: Selective vacuolar degeneration in dystrophin deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71., *Circulation*, 117, 2437-2448, 2008
14. Tanihata J, Suzuki N, Miyagoe-Suzuki Y, Imaizumi K, O Takeda S: Downstream utrophin enhancer is required for expression of utrophin in the skeletal muscle., *J Gene Med*, 10, 702-713, 2008
15. Yuasa K, Nakamura A, Hijikata T, O Takeda S: Dystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscle., *BMC Musculoskelet Disord*, 9, 1, 2008
16. Suzuki N, Motohashi N, Uezumi A, Fukada SI, Yoshimura T, Itoyama Y, Aoki M, Miyagoe-Suzuki Y, O Takeda S: NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS., *J Clin Invest*, 117, 2468-2476, 2007
17. Ikemoto M, Fukada SI, Uezumi A, Masuda S, Miyoshi H, Yamamoto H, Wada MR, Masubuchi N, Miyagoe-Suzuki Y, O Takeda S: Autologous Transplantation of SM/C-2.6(+) Satellite Cells Transduced with Micro-dystrophin CS1 cDNA by Lentiviral Vector into mdx Mice., *Mol Ther*, 15, 2178-2185, 2007
18. Fukada S, Uezumi A, Ikemoto M, Masuda S, Segawa M, Tanimura N, Yamamoto H, Miyagoe-Suzuki Y, O Takeda S: Molecular Signature of Quiescent Satellite Cells In Adult Skeletal Muscle., *Stem Cells*, 25, 2448-2459, 2007
19. Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, Nakamura A, Hijikata T, Miyagoe-Suzuki Y, O Takeda S: Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products., *Gene Ther*, 14, 1249-1260, 2007
20. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, O Takeda S, Ikeda SI: Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ)., *BMC Musculoskelet Disord*, 8, 54, 2007
21. Naoki Suzuki, Yuko Miyagoe-Suzuki, O Shin'ichi Takeda: Gene Therapy for Duchenne Muscular Dystrophy., *Future Neurology*, Vol. 2(1), 87-96, 2007

研究分担者：後藤雄一

1. Kobayashi A, Ogoto Y, Nagata M, Yamaguchi Y. Granular swollen epithelial cells: a histological and diagnostic marker for mitochondrial nephropathy. *Am J Surg Pathol* 34:262-270, 2010.
2. Shimojima K, Komoike Y, Tohyama J, Takahashi S, Páez MT, Nakagawa E, Ogoto Y, Ohno K, Ohtsu M, Oguni H, Osawa M, Higashinakagawa T, Yamamoto T: *TULIP1 (RALGAP1)* haploinsufficiency with brain development delay., *Genomics*, 94:414-422, 2009
3. Tanaka N, Ogoto Y, Akanuma J, Kato M, Kinoshita T, Yamashita F, Tanaka M, Asada T: Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease., *Mitochondrion*, 10:32-37, 2009.
4. Kitamura K, Itou Y, Yanazawa M, Ohsawa M, Suzuki-Migishima R, Umeki Y, Hohjoh H, Yanagawa Y, Shinba T, Itoh M, Nakamura K, Ogoto Y: Three human *ARX* mutations cause the lissencephaly-like and mental retardation with epilepsy-like pleiotropic phenotypes in mice., *Hum Mol Genet*, 18, 3708-3724, 2009.
5. Mimaki M, Ichiyama T, Isumi H, Furukawa S, Akasaka M, Kamei A, Komaki H, Nonaka I, Ogoto Y: Different effects of novel mtDNA G3242A and G3244A base changes adjacent to a common A3243G mutation in patients with mitochondrial disorders., *Mitochondrion*, 9, 115-122, 2009.
6. Iizuka T, Ogoto Y, Miyakawa S, Sato M, Z Wang, Suzuki K, Hamada J, Kurata A, Sakai F: Progressive carotid artery stenosis with a novel tRNA phenylalanine mitochondrial DNA mutation., *J Neurol. Sci.*, 278, 35-40, 2009.
7. Takano K, Nakagawa E, Inoue K, Kamada F, Kure S, Ogoto Y: Japanese Mental Retardation Consortium. Loss-of-function mutation in the *FTSJ1* gene causes nonsyndromic X-linked mental retardation in a Japanese family., *Am J Med Genet Part B Neuropsychiatr Genet* , 147B, 479-484, 2008.
8. Yamashita S, Nishino I, Nonaka I, Ogoto Y: Genotype and phenotype analyses in 136 patients with single-large mitochondrial DNA deletions., *J Hum Genet*, 53, 598-606, 2008.
9. Itoh M, Suzuki Y, Sugai K, Ozuka N, Ohsawa M, Otsuki T, Ogoto Y: Progressive leukoencephalopathy associated with aluminum deposits in myelin sheath., *J Child Neurol*, 23, 938-943, 2008.
10. Itoh M, Ide S, Takashima S, Kudo S, Nomura Y, Segawa M, Kubota T, Mori H, Tanaka S, Horie H, Tanabe Y, Ogoto Y: Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains., *J Neuropathol Exp Neurol*, 66, 117-123, 2007.

研究分担者：大森崇

1. Ono M, Omori T, Nitta H: Is the midnight-to-midnight average concentration of pollutants an appropriate exposure index for a daily mortality study?, *Journal of Exposure Science & Environmental Epidemiology*, 17, 84-87, 2007
2. 大森崇: 重篤な有害事象を速く検出するためのシグナル検出法の検討, *日本統計学会誌*, 36 (2), 195-204, 2007
3. Omori T, Sozu T: Variance of the stimulation index for the local lymph node assay., *Alternative to Animal Testing and Experimentation*, 12, 212-217, 2007.
4. Omori T, Ikarashi Y, Kanazawa Y, Idehara K, Kojima H, Sozu T, Arima K, Goto H, Hanada T, Inoda T, Kosaka T, Maki E, Morimoto T, Shinoda S, Shinoda N, Takeyoshi M, Tanaka M, Uratani M, Usami M, Yamanaka A, Yoneda T, Yoshimura I, Yuasa A: Validation studies on an alternative endpoint for the local lymph node assay (LLNA-DA): Importance of study management., *Alternative to Animal Testing and Experimentation* 14 , Special issue, 429-432, 2008
5. Omori T, Idehara K, Kojima H, Sozu T, Arima K, Goto H, Hanada T, Ikarashi Y, Inoda T, Kanazawa Y, Kosaka T, Maki E, Morimoto T, Shinoda S, Shinoda N, Takeyoshi M, Tanaka M, Uratani M, Usami M, Yamanaka A, Yoneda T, Yoshimura I, Yuasa A: Interlaboratory validation of the modified murine local lymph node assay based on adenosine triphosphate measurement., *Journal of Pharmacological and Toxicological Methods*, 58, 11-26, 2008
6. Lovell D P, Omori T: Statistical issues in the use of the comet assay., *Mutagenesis*, 23, 178-182, 2008
7. Basketter D, Cockshott A, Corsini E, Gerberick G.F., Idehara K, Kimber I, Loveren H. V., Matheson J, Mehling A, Omori T, Rovida C, Sozu T, Takeyoshi M, Casati S: An evaluation of performance standards and non-radioactive endpoints for the local lymph node assay., *ATLA*, 36, 243-257, 2008

研究分担者：山岸美奈子

1. Akemi Tamaura, Minako Yamagishi, Osamu Saitou: Proposal on establishing a “clozapine coordinator”: based on the role and experience of clinical research coordinator during phase III clinical trial., *International Clinical Psychopharmacology*, Vol 22, No 5, 2007

研究分担者：村田美穂

1. Asanuma M, Miyazaki I, Diaz-Corrales F.J, Kimoto N, Kikkawa Y, Takeshima M, Miyoshi K, Murata M: Neuroprotective effects of zonisamide target astrocyte., *Ann Neurol* in press
2. Saitoh Y, Ogawa M, Naito Y, Komatsuzaki Y, Tagaya H, Arima K, Tamaoka A, Kitamoto T,

- Murata M: Discordant clinicopathological phenotypes in a Japanese kindred of fatal familial insomnia., *Neurology*, 74, 86-89, 2010
3. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, ○Murata M, Nakamura Y, Toda T: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease., *Nature Genetics*, 41, 1303-1307, 2009
 4. Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, Goto J, Fukuda Y, Date H, Iwata A, Yamamoto M, Hattori N, ○Murata M, Toda T, Tsuji S: Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease., *Arch Neurol*, 66(5), 571-576, 2009
 5. ○Murata M: Levodopa in the early treatment of Parkinson's disease., *Parkinsonism & Related Disorders*, 15(1), S17-S20, 2009
 6. Mizuta I, Tsunoda T, Satake W, Nakabayashi Y, Watanabe M, Takeda A, Hasegawa K, Nakashima K, Yamamoto M, Hattori N, ○Murata M, Toda T: Calbindin 1, fibroblast growth factor 20, and α -synuclein in sporadic Parkinson's disease., *Hum Genet*, 124, 89-94, 2008
 7. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N, ○Murata M: Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation., *Neurosci Res*, 60, 106-113, 2008
 8. Ota M, Sato M, Saitoh Y, Endo F, ○Murata M, Asada T: Diffusion tensor imaging in familial spastic paraplegia with mental impairment and thin corpus callosum., *Magn Reson Med Sci*, 7, 163-167, 2008
 9. Tomiyama H, Mizuta I, Yuanzhe Li, Funayama M, Yoshiho H, Lin Li, ○Murata M, Yamamoto M, Kubo S, Mizuno Y, Toda T, Hattori N: LRRK2 P755L variant in sporadic Parkinson's disease., *J Hum Genet*, 53, 1007-1011, 2008
 10. Kobayashi A, Arima K, Ogawa M, ○Murata M, Fukuda T, Kitamoto T: Plaque-type deposition of prion protein in the damaged white matter of sporadic Creutzfeldt-Jakob disease MM1 patients., *Acta Neuropathol*, 116, 561-566, 2008
 11. Okamoto T, Ogawa M, Lin Y, ○Murata M, Miyake S, Yamamura T: Treatment of neuromyelitis optica: Current debate., *Therapeutic Advances in Neurological Disorders*, 1, 43-52, 2008
 12. Amino T, Ishikawa K, Toru S, Ishiguro T, Sato N, Tsunemi T, ○Murata M, Kobayashi K, Inazawa J, Toda T, Mizusawa H: Redefining the disease locus of 16q22.1-linked autosomal dominant cerebellar ataxia., *J Hum Genet*, 52, 643-649, 2007
 13. Satake W, Mizuta I, Suzuki S, Nakabayashi Y, Ito C, Watanabe M, Takeda A, Hasegawa K, Sakoda S, Yamamoto M, Hattori N, ○Murata M, Toda T: Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population., *Neuroreport*, 18, 937-940, 2007

14. Tagawa K, Marubuchi S, Qi ML, Enokido Y, Tamura T, Inagaki R, Murata M, Kanazawa I, Wanker EE, Okazawa H: The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes., *J Neurosci*, 27, 868-880, 2007
15. Funayama M, Li Y, Tomiyama H, Yosino H, Imamichi Y, Yamamoto M, Murata M, Toda T, Mizuno Y, Hattori N: LRRK2 G2385R variant is a risk factor for Parkinson disease in Asian population., *Neuro Report*, 18, 273-275, 2007
16. Murata M, Hasegawa K, Kanazawa I, The Japan Zonisamide on PD Study Group: Zonisamide improves motor function in Parkinson disease. A randomized, double-blind study., *Neurology*, 68, 45-50, 2007
17. Nishioka K, Hayashi S, Farrer N J, Singleton A B, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizuno Y, Hattori N: Clinical Heterogeneity of α -Synuclein Gene Duplication in Parkinson's Disease., *Ann Neurol*, 59, 298-309, 2006
18. Murata M: Pharmacokinetics of L-dopa. Special reference to food and aging., *J Neurol*, 253[Suppl 3] III/47-III/52, 2006
19. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y, Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T: Multiple candidate gene analysis identifies α -synuclein as a susceptibility gene for sporadic Parkinson's disease., *Hum Mol Genet*, 15(7), 1151-1158, 2006
20. 山本敏之, 大矢 寧, 古澤嘉彦, 埜中征哉, 村田美穂: 反復する無自覚性低血糖の治療に Pioglitazone が有効であった筋強直性ジストロフィーの 1 例, *臨床神経*, 49(10), 641-645, 2009
21. 千原典夫, 山本敏之, 林 幼偉, 塚本 忠, 小川雅文, 村田美穂: 脊椎後彎と食堂裂孔子ヘルニアがレボドパ吸収に影響したパーキンソン病の 82 歳女性例, *臨床神経*, 49(8), 493-496, 2009
22. 村田美穂: パーキンソン病診療 Q&A110, 中外医学社, 176-177, 2009
23. 村田美穂: パーキンソン病の薬物治療, *BRAIN and NERVE*, 61(4), 464-467, 2009
24. 村田美穂: 脊髄小脳変性症 薬物療法, *Clinical Neuroscience*, 27(1), 92-94, 2009
25. 村田美穂: パーキンソン病の四大徴候～パーキンソン病診断のコツと Pitfall～ *Frontiers in Parkinson Disease*, 2(2), 28-31, 2009
26. 村田美穂: パーキンソン病—基礎・臨床研究のアップデート— 薬物療法 新規治療薬—ゾニサミド—, *日本臨床*, 67(4), 401-405, 2009
27. 村田美穂: 進行性核上性麻痺, 神経疾患最新の治療, 2009-2011, 188-189, 2009
28. 村田美穂: パーキンソン病の治療, 薬物療法の up to date, *臨床神経学*, 48(11), 986-988, 2008
29. 村田美穂, 久野貞子: パーキンソン病における DBS アンケート結果 —満足度と問題

- 点一, *Pharma Medica*, 26(3), 6-11, 2008
30. ○村田美穂: パーキンソン病治療の変遷と今後の展望 薬物療法 L-dopa の効果と安全性に関する最近の知見, *Prog. Med*, 10(28), 2347-2350, 2008
 31. ○村田美穂: ゾニサミドの抗パーキンソン病効果, 成人病と生活習慣病, 38(8), 967-970, 2008
 32. 岡本智子, ○村田美穂: プライマリケア時代の症候の診方—振戦—, 診断と治療 増刊号, 96, 149-155, 2008
 33. ○村田美穂: パーキンソン病薬物療法のメリット・デメリット, *医学のあゆみ*, 225(5), 395-399, 2008
 34. ○村田美穂: パーキンソン病における併用療法のあり方と注意点, *老年医学*, 46, 365-369, 2008
 35. ○村田美穂: パーキンソン病治療薬の問題点と今後望まれる薬剤, *日本病院薬剤師会雑誌*, 131, 281-284, 2008
 36. 青木吉嗣, 山本敏之, 尾方克久, 大矢 寧, 小川雅文, ○村田美穂: 嚥下造影検査が重症筋無力症増悪の評価に有効であった 1 例, *臨床神経*, 47(10), 669-671, 2007
 37. 青木吉嗣, 岡本智子, 大矢 寧, 小川雅文, ○村田美穂, 山村 隆, 大槻泰介: 多発性硬化症が疑われた, 頸髄海綿状血管腫の 49 歳女性例, *脊椎脊髄ジャーナル*, 20(3), 273-278, 2007
 38. ○村田美穂: 話題のくすり エンタカポン, *日本病院薬剤師会雑誌*, 43(11), 1579-1582, 2007
 39. ○村田美穂: 抗てんかん薬 zonisamide の Parkinson 病に対する効果, *医学のあゆみ*, 222(10), 829-830, 2007
 40. ○村田美穂: ジストニアの内科的治療の現状, *神経内科*, 67(1), 62-65, 2007
 41. ○村田美穂: 薬物治療: 我が国初の新規治療薬の開発に向けて - 新規抗パーキンソン病薬ゾニサミドの開発 -, *最新医学*, 62(7), 40-45, 2007
 42. ○村田美穂: パーキンソン病の治療戦略 早期患者への治療方針, *内科*, 99(5):787-791.
 43. ○村田美穂: Parkinson 病患者における日中睡眠過多と突発的睡眠, *神経内科*, 60(1), 67-71, 2007
 44. ○村田美穂: パーキンソン病の診察のポイント, *MB Med Reha*, 76, 7-12, 2007
 45. ○村田美穂: 長谷川一子, ディベート パーキンソン病の初期治療はレボドパか、ドパミンアゴニストか?, *Clini Neurosci*, 25, 240-241, 2007
 46. ○村田美穂: パーキンソン病の治療 薬物療法, *Clini Neurosci*, 25, 82-85, 2007

研究分担者: 玉浦明美

1. ○Akemi Tamaura, ○Minako Yamagishi, Osamu Saitou: Proposal on establishing a “clo

zapine coordinator”: based on the role and experience of clinical research coordinator during phase III clinical trial., *International Clinical Psychopharmacology*, Vol 22, No 5, 2007

研究分担者：山田光彦

1. 米本直裕, ○山田光彦: 研究デザインの妥当性 (基礎講座: 老年精神医学研究の進め方と発表の仕方), *老年精神医学*, 20(11), 2009.
2. Kodaka M, Tanaka S, Takahara M, Inamoto A, Shirakawa S, Inagaki M, Kato N, ○Yamada M: Misalignments of Rest-activity Rhythms in Inpatients with Schizophrenia and Relevant Factors to Rhythm Characteristics., *Psychi Clin Neurosci*, 2010.
3. Kodaka M, Postuvan V, Inagaki M, ○Yamada M: A Systematic Review of Scales that Measure Attitudes toward Suicide., *Int J Social Psychiatry*, 2009 (in press).
4. ○Yamada M, Takahashi K, Ukai W, Hashimoto E, Saito T, Yamada M: Neuroserpin expression in early stages of neurogenesis in adult rat hippocampus., *Neuroreport*, 2009 (in press).
5. 稲垣正俊, ○山田光彦: 自殺防止に向けての国の取り組み, *精神科治療学*, 24(10), 1289-1293, 2009.
6. 稲垣正俊, 三島和夫, ○山田光彦: 精神疾患対策モデルからのアプローチ, *自殺予防と危機介入*, 28 (1), 10-14, 2009.
7. ○山田光彦: ライフサイクルと社会精神医学, 老年期. 日本社会精神医学会編集, *社会精神医学*, 医学書院, 179-187, 2009, 東京
8. Takahashi K, Saitoh A, Yamada M, Maruyama Y, Hirose N, Kamei J, ○Yamada M: Gene expression profiling reveals complex changes in the olfactory bulbectomy model of depression after chronic treatment with antidepressants., *J Pharmacol Sci*, 108(3), 320-34, 2008 Nov.
9. Kishimoto M, Ujike H, Okahisa Y, Kotaka T, Takaki M, Kodama M, Inada T, ○Yamada M, Uchimura N, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S: The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population., *Behavioral and Brain Functions*, 4 (37), 2008 (online publication).
10. Maruyama Y, ○Yamada M, Takahashi K, Yamada M: Ubiquitin ligase Kf-1 is involved in the endoplasmic reticulum-associated degradation pathway., *Biochem Biophys Res Comm*, 374, 737-741, 2008.
11. Yamada M, Shida Y, Takahashi K, Tanioka T, Nakano Y, Tobe T, ○Yamada M: Prg1 is regulated by the basic helix-loop-helix transcription factor Math2., *J Neurochem*, 106, 2375-2384, 2008.
12. Saitoh A, ○Yamada M, Yamada M, Takahashi K, Yamaguchi K, Murasawa H, Nakatani A,

- Tatsumi Y, Hirose N, Kamei J: Antidepressant-like effects of the delta-opioid receptor agonist SNC80([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide]in an olfactory bulbectomized rat model., *Brain Res*, 1208, 160-169, 2008.
13. Uhl GR, Drgon T, Liu QR, Johnson C, Walther D, Komiyama T, Harano M, Sekine Y, Inada T, Ozaki N, Iyo M, Iwata N, Yamada M, Sora I, Chen CK, Liu HC, Ujike H, Lin SK: Genome-wide association for methamphetamine dependence: convergent results from 2 samples., *Arch Gen Psychiatry*, 65(3), 345-355, 2008.
 14. Morita Y, Ujike H, Tanaka Y, Kishimoto M, Okahisa Y, Kotaka T, Harano M, Inada T, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S: The Glycine Transporter 1 Gene (GLYT1) Is Associated With Methamphetamine-Use Disorder., *American Journal of Medical Genetics Part B (Neuropsychiatric Genetics)*, 147B, 54-58, 2008.
 15. Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S: The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis., *BIOL PSYCHIATRY*, 63, 191-196, 2008.
 16. Otani K, Ujike H, Sakai A, Okahisa Y, Kotaka T, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S: Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence., *Neurosci Lett*, 434(1), 88-92, 2008.
 17. 三好出, 山田光彦: 精神疾患領域における国際共同治験ー実施施設の観点を交えてー, *PHARMSTAGE*, 7 (10), 25-28, 2008.
 18. 山田光彦, 高橋清久: 自殺対策のための戦略研究 : J-MISP について, *精神神経学雑誌*, 110 (3), 210-215, 2008.
 19. 山田光彦, 山田美佐, 高橋弘, 丸山良亮, 尾崎紀夫, 岩井仲生: 新規うつ病治療的分子としての frizzled-3 protein の可能性, *臨床薬理の進歩*, 29, 221-225, 2008. 5
 20. 山田光彦, 大内幸恵, 稲垣正俊, 自殺対策におけるインターネットの活用, *精神科治療学*, 23(5), 525-530, 2008.
 21. 山田光彦: 海外における自殺対策の取り組みとエビデンス, *学術の動向 SCJ フォーラム* 2008-3, 20-25, 2008
 22. Ikeda M, Ozaki N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Kishi T, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Iwata N: Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia., *Genes Brain Behav*, 6(1), 107-112, 2007.
 23. Saitoh A, Yamaguchi K, Tatsumi Y, Murasawa H, Nakatani A, Hirose N, Yamada M, Yamada M, Kamei J: Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats.,

- Psychopharmacol, 191(4), 857-865, 2007.
24. Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, Maeda K, Suzuki Y, Mashimo Y, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Hata A, Sawa A, Iyo M: Identification of Functional Polymorphisms in the Promoter Region of the Human PICK1 Gene and Their Association With Methamphetamine Psychosis., *Am J Psychiatry*, 164 (7), 1105-1114, 2007.
 25. Kamei J, Hirose N, Oka T, Miyata S, Saitoh A, Yamada M: Effects of Methylphenidate on the Hyperemotional Behavior in Olfactory Bulbectomized Mice by Using the Hole-Board Test., *J Pharmacol Sci*, 103, 175-180, 2007.
 26. 山田光彦: 自殺の現状とその対策における精神科医療の役割, *日本社会精神医学会雑誌*, 16(1), 73-78, 2007.
 27. 山田光彦: 治療法の進歩 自殺予防対策, *日本臨床*, 65 (9), 1675-1678, 2007.
 28. 山田光彦, 高橋弘, 志田美子, 丸山良亮, 山田美佐, 樋口輝彦: うつ病治癒機転に重要な転写因子が制御するターゲット遺伝子群の探索と機能の検討, *精神薬療研究年報*, 39, 53-58, 2007.
 29. 山田光彦, 高橋清久: 自殺対策のための戦略研究 J-MISP, *医学のあゆみ*, 221(3), 233-236, 2007.
 30. 米本直裕, 中井亜弓, 山田光彦: 人を対象とした医学研究を行うときにまず考えるべきこと, *分子精神医学*, 7(2), 44-46, 2007.
 31. 山田光彦: 気分障害. 久野貞子, 樋口輝彦編, *こころの健康科学研究の現状と課題—今後の研究のあり方について*, 監修: 財団法人精神・神経科学振興財団, 112-120, 2007.

研究分担者: 伊藤弘人

1. Ito H: Quality and performance improvement for mental healthcare in Japan. *Curr Opin Psychiatry* 22: 619-622, 2009.
2. 奥村泰之, 三澤史奇, 中林哲夫, 伊藤弘人: 統合失調症患者への非定型抗精神病薬治療と糖尿病のリスク: メタ分析. *臨床精神薬理* 13: 317-325, 2010
3. 伊藤弘人: 身体疾患とうつ病: これからの取り組み. *精神科治療学* 24: 1529-1533, 2009.
4. 伊藤弘人: 身体疾患に伴ううつ病. *医療の広場* 49: 4-8, 2009.
5. Ito H, Kawano K, Kawashima D, Kawanishi C: Responses to patients with suicidal ideation among different specialties in general hospitals. *Gen Hosp Psychiatry* 30: 578-580, 2008.
6. Koyama A, Ito H, Nakanishi M, Sawamura K, Higuchi T: Addition of

antipsychotics to medication regimens during schizophrenic inpatient care. *Psychiatry Clin Neurosci* 62: 56-64, 2008.

研究分担者：米本直裕

1. Nagai S, Andrianarimanana D, Rabesandratana N, OYonemoto N, Nakayama T, Mori R. Earlier versus later continuous Kangaroo Mother Care (KMC) for stable low-birth-weight infants: a randomized controlled trial. *Acta Paediatr.* 2010 Jan 27. [Epub ahead of print]
2. Mori R, OYonemoto N, Fitzgerald A, Tullus K, Verrier-Jones K, Lakhanpaul M. Diagnostic performance of urine dipstick testing in children with suspected UTI: a systematic review of relationship with age and comparison with microscopy. *Acta Paediatr.* 2010 Jan 5. [Epub ahead of print]
3. O米本直裕 山田光彦 老年医学研究の進め方と発表の仕方(2) 研究デザインの妥当性 老年精神医学雑誌 20 (11) p1297-1304
4. Matsuoka Y, Nishi D, OYonemoto N, Nakajima S, Kim Y: Towards an Explanation of Inconsistent Rates of Posttraumatic Stress Disorder across Different Countries: Infant Mortality Rate as a Marker of Social Circumstances and Basic Population Health., *Psychotherapy and Psychosomatics*, 18;79(1), 56-57, 2009
5. Hirayasu Y, Kawanishi C, OYonemoto N, Ishizuka N, Okubo Y, Sakai A, Kishimoto T, Miyaoka H, Otsuka K, Kamijo Y, Matsuoka Y, Aruga T: A randomized controlled multicenter trial of post-suicide attempt case management for the prevention of further attempts in Japan (ACTION-J)., *BMC Public Health*, 26; 9: 364, 2009
6. Nishiyama C, Iwami T, Kawamura T, Ando M, Kajino K, OYonemoto N, Fukuda R, Yuasa H, Yokoyama H, Nonogi H: Effectiveness of simplified chest compression-only CPR training program with or without preparatory self-learning video: a randomized controlled trial., *Resuscitation*, 80(10), 1164-8, 2009
7. Matsuoka Y, Nishi D, Nakajima S, OYonemoto N, Noguchi H, Otomo Y, Kim Y: Impact of psychiatric morbidity on quality of life after motor vehicle accident at 1-month follow up., *Psychiatry and Clinical Neurosciences*, 63(2), 235-7, 2009
8. Uetani K, Nakayama T, Ikai H, OYonemoto N, Moher D: Quality of reports on randomized controlled trials conducted in Japan: evaluation of adherence to the CONSORT statement., *Internal Medicine*, 48(5), 307-13, 2009
9. Nishi D, Matsuoka Y, Noguchi H, Sakuma K, OYonemoto N, Yanagita T, Homma M, Kanba S, Kim Y: Reliability and validity of the Japanese version of the Peritraumatic Distress Inventory., *General Hospital Psychiatry*, 31(1), 75-9, 2009
10. Matsuoka Y, Nishi D, Nakajima S, OYonemoto N, Hashimoto K, Noguchi H, Homma M, Otomo Y, Kim Y: The Tachikawa cohort of motor vehicle accident study investigating psychological distress: design, methods and cohort profiles., *Social Psychiatry and Psychiatric Epidemiology*, 44(4), 333-40, 2009
11. Ono Y, Awata S, Iida H, Ishida Y, Ishizuka N, Iwasa H, Kamei Y, Motohashi Y, Nakagawa A, Nakamura J, Nishi N, Otsuka K, Oyama H, Sakai A, Sakai H, Suzuki Y, Tajima M, Tanaka E, Uda H, OYonemoto N, Yotsumoto T, Watanabe N: A community intervention trial of multimodal suicide prevention program in Japan: a novel multimodal community intervention program to prevent suicide and suicide attempt in Japan., *NOCOMIT-J. BMC Public Health*, 15; 8: 315, 2008
12. Nishiyama C, Iwami T, Kawamura T, Ando M, OYonemoto N, Hiraide A, Nonogi H: Effectiveness of simplified chest compression-only CPR training for the general public: a randomized controlled trial., *Resuscitation*, 79(1), 90-6, 2008

13. Iwami T, Kawamura T, Hiraide A, Berg RA, Hayashi Y, Nishiuchi T, Kajino K, Yonemoto N, Yukioka H, Sugimoto H, Kakuchi H, Sase K, Yokoyama H, Nonogi H: Effectiveness of bystander-initiated cardiac-only resuscitation for patients with out-of-hospital cardiac arrest., *Circulation*, 116(25), 2900-7, 2007
14. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T: A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer., *Japanese Journal of Clinical Oncology*, 37(11), 843-51, 2007

研究分担者：中村治雅

1. 中村治雅：臨床研究をめぐる国内と海外の現状，*臨床薬理*，40(4)，137-140，2009
2. 中村治雅，筋ジストロフィー患者登録データベース特にDuchene型筋ジストロフィーに関連して．*小児筋疾患診療ハンドブック 診断と治療社*，2009，99-100
3. 中村治雅，宇山佳明：最近の医薬品開発の現状と治験デザイン バイオマーカーと臨床的エンドポイント，*神経治療学*，23(6)，607-13，2006

